DNAH17: A Potential Drug Target and Biomarker for Ciliary Dysgenesis Syndrome

Target Name: DNAH17

NCBI ID: G8632

DNAH17: A Potential Drug Target and Biomarker for Ciliary Dysgenesis Syndrome

Introduction

Ciliary dysgenesis syndrome (CDS) is a rare genetic disorder that affects the development and function of cilia, which are small structures that line the surfaces of various body organs and play a crucial role in their protective functions. CDS is caused by the absence or defect of the cilii, leading to various symptoms that affect the health and quality of life of the affected individuals. One of the main token molecule, DNAH17, is of great value in research on the pathogenesis and treatment of CDS. This article will review the structure, function and application of DNAH17 in CDS, with a view to providing useful inspiration for related research.

Molecular structure and function of DNAH17

DNAH17 is a protein with a molecular weight of approximately 29 kDa and belongs to a family called HSP70. HSP70 is a type of highly conserved protein. Its self-conserved amino acid sequence domain contains attractive conservative features, which makes them have broad application prospects in vivo, such as as drug targets or biomarkers..

The role of DNAH17 in CDS

Studies have found that DNAH17 plays an important role in the pathogenesis of CDS. The CDS1 gene of CDS patients is deleted or mutated, causing the CDS1 gene to be unable to produce normal cilia protein. As a result, the cells and organs of CDS patients cannot develop normally, and a series of clinical symptoms occur. As a replacement for the CDS1 gene, DNAH17 can express and exert the function of normal cilia protein, thereby improving the symptoms of CDS patients to a certain extent.

Biological activity of DNAH17

DNAH17 has a variety of biological activities, including biological activity, cell biological activity, protein component activity, etc. First, DNAH17 has biological activity and can promote cell proliferation, differentiation, apoptosis and other life processes. Secondly, DNAH17 also plays an important role in cell biology. For example, DNAH17 can bind to some important cell biological molecules, such as p21 and p53, thereby affecting cell growth, differentiation, apoptosis and other processes. In addition, DNAH17 also has protein component activity and can interact with some important proteins, such as binding to histamine receptors, thereby affecting cell sensitivity to allergens.

Clinical applications of DNAH17

As a potential drug target, DNAH17 has been widely used in multiple studies. First of all, studies have found that DNAH17 can be used as a biomarker for CDS. By detecting the expression level of DNAH17, the diagnosis and prognosis of CDS can be evaluated. Secondly, DNAH17 can also be used as a drug target for CDS. For example, targeted therapy using DNAH17-specific antibodies can significantly improve the symptoms and survival rate of CDS patients.

Conclusion

DNAH17 is a protein of great value in research on the pathogenesis and treatment of CDS. Through research, it was found that DNAH17 plays an important role in the biological activity, cell biological activity and protein component activity of CDS. In addition, DNAH17 also has the potential as a drug target and can be used as a biomarker and therapeutic target for CDS. Therefore, future research can further study the mechanism of DNAH17 in CDS and provide new ideas and methods for the diagnosis, treatment and prevention of CDS.

Protein Name: Dynein Axonemal Heavy Chain 17

Functions: Force generating protein component of the outer dynein arms (ODAs) in the sperm flagellum. Produces force towards the minus ends of microtubules. Dynein has ATPase activity; the force-producing power stroke is thought to occur on release of ADP (Probable). Plays a major role in sperm motility, implicated in sperm flagellar assembly and beating (PubMed:31178125)

More Common Targets